最新报道:Santhera Pharmaceuticals has set the conversion price for its convertible bond at CHF 13.5446, representing a 10% premium to the VWAP of its shares on September 23, 2025. The bond carries a 7% coupon, lower than the previous issue, with a total principal amount of CHF 20.132 million including the exchange of the prior bond.